Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1)

Brief summary

This study will be conducted to evaluate the efficacy and safety of YOLT-203 in children and adults with Primary Hyperoxaluria Type 1. After the initial randomized, 6-month double-blind, placebo-controlled period, participants who were initially assigned to placebo will receive a single-dose of YOLT-203 treatment whereas participants in the YOLT-203 group will receive a single-dose of placebo infusion. For patients interested in additional information on how to participate, please follow this link: https://mytomorro.ws/ph1trial.

Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.

Trial details

status

RECRUITING

phase

PHASE2

study type

INTERVENTIONAL

enrollment

36

sponsor

YolTech Therapeutics Co., Ltd

conditions

Primary Hyperoxaluria Type 1; PH1

interventions

GENETIC: YOLT-203; DRUG: Placebo

start date

2026-09-16

start date type

ACTUAL

primary completion date

2027-08-01

has results

false

data source

ClinicalTrials.gov

data processed

2026-10-29T09:00:05

modifications

selected fields only; whitespace normalized; brief summary truncated to 2,000 characters